Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · TARS · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
44
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Tarsus Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
TARS insider buying and selling by quarter
TARS insider selling · TARS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · TARS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
TARS executive sell shares · TARS board member insider trading · TARS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 24, 2026 | PYOTT DAVID E I Director | Option | 1,383 | — | Form 4 |
| Mar 20, 2026 | Neervannan Seshadri COO | Sale | 2,989 | $200K | Form 4 |
| Mar 17, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,029 | $280K | Form 4 |
| Mar 18, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,071 | $280K | Form 4 |
| Mar 19, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,174 | $280K | Form 4 |
| Mar 17, 2026 | Wahl Bryan General Counsel | Sale | 4,084 | $284K | Form 4 |
| Mar 18, 2026 | Wahl Bryan General Counsel | Sale | 4,125 | $283K | Form 4 |
| Mar 19, 2026 | Wahl Bryan General Counsel | Sale | 4,231 | $283K | Form 4 |
| Mar 17, 2026 | Neervannan Seshadri COO | Sale | 3,125 | $217K | Form 4 |
| Mar 18, 2026 | Neervannan Seshadri COO | Sale | 3,610 | $248K | Form 4 |
| Mar 19, 2026 | Neervannan Seshadri COO | Sale | 4,589 | $307K | Form 4 |
| Mar 17, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,286 | $298K | Form 4 |
| Mar 18, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,330 | $298K | Form 4 |
| Mar 19, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,440 | $297K | Form 4 |
| Mar 17, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 375 | $26K | Form 4 |
| Mar 18, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 379 | $26K | Form 4 |
| Mar 19, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 390 | $26K | Form 4 |
| Mar 17, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,111 | $147K | Form 4 |
| Mar 18, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,133 | $147K | Form 4 |
| Mar 19, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,186 | $146K | Form 4 |
| Mar 17, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 10,972 | $762K | Form 4 |
| Mar 18, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 11,667 | $802K | Form 4 |
| Mar 19, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 11,964 | $802K | Form 4 |
| Mar 16, 2026 | LINK WILLIAM J PHD Director | Sale | 3,629 | $247K | Form 4 |
| Mar 16, 2026 | LINK WILLIAM J PHD Director | Sale | 8,378 | $578K | Form 4 |
Whitfield Dianne C.
Chief Human Resources Officer
Date
Mar 17
Shares
4,029
Price
$69.42
Value
$280K
Whitfield Dianne C.
Chief Human Resources Officer
Date
Mar 18
Shares
4,071
Price
$68.71
Value
$280K
Whitfield Dianne C.
Chief Human Resources Officer
Date
Mar 19
Shares
4,174
Price
$67.00
Value
$280K
Mottiwala Aziz
Chief Commercial Officer
Date
Mar 17
Shares
4,286
Price
$69.42
Value
$298K
Mottiwala Aziz
Chief Commercial Officer
Date
Mar 18
Shares
4,330
Price
$68.71
Value
$298K
Mottiwala Aziz
Chief Commercial Officer
Date
Mar 19
Shares
4,440
Price
$67.00
Value
$297K
Lin Elizabeth Yeu
Chief Medical Officer
Date
Mar 17
Shares
375
Price
$69.42
Value
$26K
Lin Elizabeth Yeu
Chief Medical Officer
Date
Mar 18
Shares
379
Price
$68.71
Value
$26K
Lin Elizabeth Yeu
Chief Medical Officer
Date
Mar 19
Shares
390
Price
$67.00
Value
$26K
Azamian Bobak R.
President/CEO and Board Chair · Director
Date
Mar 17
Shares
10,972
Price
$69.42
Value
$762K
Azamian Bobak R.
President/CEO and Board Chair · Director
Date
Mar 18
Shares
11,667
Price
$68.71
Value
$802K
Azamian Bobak R.
President/CEO and Board Chair · Director
Date
Mar 19
Shares
11,964
Price
$67.00
Value
$802K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About TARS insider trading
TARS insider trades
Tarsus Pharmaceuticals, Inc. (TARS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Whitfield Dianne C. (Chief Human Resources Officer), Neervannan Seshadri (COO), LINK WILLIAM J PHD (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. TARS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Tarsus Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
TARS insider trading · 5 questionsThe insiders of Tarsus Pharmaceuticals, Inc. (TARS) include executives and directors such as Whitfield Dianne C. (Chief Human Resources Officer), Neervannan Seshadri (COO), LINK WILLIAM J PHD (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026